Compare PRGS & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGS | IMTX |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1995 | N/A |
| Metric | PRGS | IMTX |
|---|---|---|
| Price | $37.86 | $9.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $49.50 | $19.00 |
| AVG Volume (30 Days) | ★ 978.1K | 352.3K |
| Earning Date | 03-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.79 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $397,572,000.00 | N/A |
| Revenue This Year | $3.70 | N/A |
| Revenue Next Year | $1.08 | $25.91 |
| P/E Ratio | $37.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.82 | $5.05 |
| 52 Week High | $51.28 | $12.41 |
| Indicator | PRGS | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.46 | 44.61 |
| Support Level | $35.52 | $9.04 |
| Resistance Level | $44.09 | $10.64 |
| Average True Range (ATR) | 2.28 | 0.55 |
| MACD | 0.56 | 0.06 |
| Stochastic Oscillator | 80.32 | 22.46 |
Progress Software Corp provides software products that enable customers to develop, deploy, and manage AI-powered applications and digital experiences. The Company operates across North America, Latin America, Europe, the Middle East and Africa (EMEA), and Asia Pacific through subsidiaries and distributors, generating a majority of its revenue from the United States. Its product portfolio includes Progress Agentic RAG, Automate MFT, Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, and WhatsUp Gold, offering solutions for application development, data connectivity, DevOps automation, managed file transfer, network security, and digital experience. It generates maximum revenue from the United States.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.